Company intelligence
Compass Pathways
We are unlocking pathways to be.
About Compass Pathways
We are Compass, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. We believe people living with mental health conditions deserve the possibility of a better future. Our initial focus is advancing COMP360, a proprietary, investigational synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability, with infrequent dosing. We’re driven by our purpose of unlocking pathways to be—opening futures filled with possibility. Together, we’re on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery. Every journey needs a Compass.
Verified activity
Signals from Compass Pathways
8 published signals
Presence & Recognition
Compass Pathways will debut Change the Tune in TRD at Psych Congress 2026 as a new U.S.-only healthcare provider education campaign focused on the neurobiology of treatment-resistant depression and navigating care pathways.
Reported by Compass Pathways
People
Compass Pathways has a strong Medical Affairs team
Reported by Kenneth H.
People
Compass Pathways is hiring an MSL Director in the West to join an amazing team.
Reported by Caroline Hostetler, PhD
Presence & Recognition
Compass Pathways was chosen as a 2026 Fierce 50 honoree in the Breakthrough category by the editors of Fierce Pharma, Fierce Biotech and Fierce Healthcare.
Reported by Solene Chevreau
Presence & Recognition
Compass Pathways was chosen as a 2026 Fierce 50 honoree in the Breakthrough category.
Reported by Lucinda Orsini
Presence & Recognition
Compass Pathways was chosen as a 2026 Fierce 50 honoree in the Breakthrough category presented by Fierce Pharma, Fierce Biotech and Fierce Healthcare.
Reported by Compass Pathways
Presence & Recognition
Compass Pathways was chosen as a 2026 Fierce 50 honoree in the Breakthrough category by the editors of Fierce Pharma, Fierce Biotech and Fierce Healthcare.
Reported by Jo Lane
Presence & Recognition
Compass Pathways is participating in the 2026 Cantor Fitzgerald Global Healthcare Conference on September 9, where its management team will participate in a fireside chat at 3:20 p.m. ET and a panel discussion titled 'PSYCH! Accessing The New Wave of Psychedelics' at 4:30 p.m. ET.
Reported by Compass Pathways